Anavex Life Sciences Corp (AVXL)

[falconer66a]

Pretty impressive. Anavex has won.

...blarcamesine (ANAVEX®2-73) did demonstrate a statistically significant slowing in cognitive decline associated with Alzheimer’s disease.
The clinical effect was complemented by two independent biomarkers: A significant reduction in pathological amyloid beta levels in plasma1, as well as a significant slowing in the rate of pathological brain atrophy2 on MRI (Magnetic Resonance Imaging)3 scans.

And...

In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P = 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo.

In anticipation of this announcement, I bought a few more AVXLs a few weeks ago. Glad I did.

The report reveals two different outcomes that the FDA will have pay attention to. First will be the evidence of a “ significant reduction in pathological amyloid beta levels” Nothing better for the predominent “amyloid is Alzheimer’s” crowd. Given the focus on amyloids by the medical research community, those data alone should seal Anavex’s future.

But, additionally demonstrated was “...a statistically significant slowing in cognitive decline associated with Alzheimer’s disease.”

Then, for those familiar with biostatistics, check the stated P values. Every single one thoroughly, incontrovertibly, validated efficacy.

The next thing to be revealed, when hundreds of Alzheimer’s patients can begin to be treated with blarcamesine, will be the discovery of blarcamesine’s plethora of favorable “downstream” effects: restoration of neuron autophagy, mitochondrial function support, proper gene expression from chromosomes, and all the others we’ve been talking about for all these years.

It’s been a long time, but blarcamesine and Anavex have won.